The analyst following ACR at BBY has reiterated his "Strong Buy recommendation" after todays announcement. Denis Hulme says "the patent news will prevent competitors developing an underarm testerone delivery technology until at least 2027 while strenghtening the protection of Acrux's drug Axiron against generic competition" and this is the clincher as far as I'm concerned...."importantly the patent gives greater certainty around future Axiron revenues and increases the likelihood that Lilly will make a bid for ACR"
Hulme has put his $4.20 price target under review.
Will be interesting as to his reviewed price, things are looking very promising for ACR.
- Forums
- ASX - By Stock
- ACR
- bby strong buy
bby strong buy
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.7¢ |
Change
0.001(1.52%) |
Mkt cap ! $19.47M |
Open | High | Low | Value | Volume |
6.8¢ | 6.9¢ | 6.3¢ | $15.12K | 225.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 99499 | 6.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 30997 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 99499 | 0.065 |
1 | 12091 | 0.064 |
1 | 60640 | 0.063 |
1 | 1700 | 0.062 |
1 | 50000 | 0.061 |
Price($) | Vol. | No. |
---|---|---|
0.067 | 30997 | 1 |
0.070 | 76714 | 1 |
0.071 | 18601 | 1 |
0.072 | 30000 | 1 |
0.079 | 50000 | 1 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
NVA
Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
MND
Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?
ACR (ASX) Chart |